Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00211549 · ClinicalTrials.gov registry record · Phase 2

An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee

A Phase 2 study of Osteoarthritis, Knee, sponsored by IDEA.

Completed
Registry status
Phase 2
Development phase
875
Enrollment target
20
Study locations

NCT00211549 is a Phase 2 study of Osteoarthritis, Knee that has completed, run by IDEA. The registered enrollment target is 875 participants, above the 570-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00211549, a Phase 2 study of Osteoarthritis, Knee, has completed, sponsored by IDEA.

COMPLETED
Registry status
Phase 2
Development phase
875 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to identify the dose(s) of IDEA-033 that will provide a meaningful effect for treating osteoarthritis of the knee.

Conditions Studied

Interventions

  • DRUG IDEA-033

Study Locations (20)

California

  • - Anaheim
  • - Encinitas
  • - Fair Oaks
  • - Garden Grove
  • - Irvine
  • - Paramount
  • - Rancho Mirage
  • - San Diego
  • - Spring Valley
  • - Temecula
  • - Vista

Alabama

  • - Birmingham
  • - Montgomery
  • Drug Research and Analysis Corporation - Montgomery
  • - Northport

Arizona

  • - Mesa
  • - Phoenix
  • - Tempe

Colorado

  • - Northglenn

Connecticut

  • - Danbury

Trial Details

FieldValue
Enrollment Target 875 participants
Start Date 2005-06
Phase Phase 2

Sponsor

IDEA

3 total trials

What the Registry Record Tells You About NCT00211549

The ClinicalTrials.gov registry entry for NCT00211549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 875 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 570-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (54% higher). The listed sponsor is IDEA, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 1 intervention - of which IDEA-033 is the first listed.

NCT00211549 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00211549 about?

NCT00211549 is a clinical study titled "An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee". The purpose of this study is to identify the dose(s) of IDEA-033 that will provide a meaningful effect for treating osteoarthritis of the knee.

What is the current status of trial NCT00211549?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 875 participants. The study started on 2005-06.

What conditions does trial NCT00211549 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee.

What interventions are being tested in trial NCT00211549?

The interventions under investigation include: IDEA-033 (DRUG).

Who is sponsoring clinical trial NCT00211549?

This trial is sponsored by IDEA, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00211549 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.